Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

Science 335 (6075): 1447-1448

Copyright © 2012 by the American Association for the Advancement of Science

Old Drug, New Hope for Alzheimer's Disease

Warren J. Strittmatter

Alzheimer's disease insidiously robs patients of the ability to remember, reason, and make informed judgments. Despite decades of research, no therapeutics are available that slow disease progression, and to date no "disease-modifying" drug has succeeded to show therapeutic benefit and to be safe. On page 1503 of this issue, Cramer et al. (1) show that a drug called bexarotene reverses the effects of neurodegeneration in a mouse model of Alzheimer's disease. The study provides new hope that decades of research examining the molecular and cellular pathways in Alzheimer's disease may soon yield disease-modifying therapies.

Departments of Medicine (Neurology) and Neurobiology, Duke University Medical Center, Durham, NC 27710, USA.


Apolipoprotein E, Statins, and Risk of Intracerebral Hemorrhage.
D. Woo, R. Deka, G. J. Falcone, M. L. Flaherty, M. Haverbusch, S. R. Martini, S. M. Greenberg, A. M. Ayres, L. Sauerbeck, B. M. Kissela, et al. (2013)
Stroke 44, 3013-3017
   Abstract »    Full Text »    PDF »
Drug Directed at ApoE Production is Successful in Mouse Models of Alzheimer Disease.
Anthony L. Komaroff, MD and Anthony L. Komaroff, MD (2013)
Journal Watch 2012, JW201204100000004
   Full Text »
Drug Directed at ApoE Production is Successful in Mouse Models of Alzheimer Disease.
Journal Watch (General) 2012, 4
   Full Text »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882